Acta Theologica
June 30, 2026
Norman Nyazema, Jo Nel
As South Africa and the global community confront the changing dynamics of cannabis decriminalization and legalization, this article examines the intricate nexus between Cannabis sativa and religion. With evolving societal perspectives and legal paradigms, the study probes into the historical underpinnings of cannabis, its chemical structure, criminalization, medicinal uses, industrial...
Pharmaceuticals (Basel, Switzerland)
June 29, 2026
Dilorom Begmatova, Liudmila Vinnikova, Natalya Zemliana et al.
Background: Adolescence is a sensitive period for brain maturation during which exposure to Δ9-tetrahydrocannabinol (THC) can induce long-lasting neurobehavioral alterations. Yet, preclinical and clinical studies report inconsistent long-term outcomes of adolescent THC exposure, ranging from clear impairments to apparently normalizing effects. We hypothesize that these discrepancies reflect...
Molecular Psychiatry
June 27, 2026
David R. Roalf, Tyler M Moore, Jacquelyn Stifelman et al.
Abstract Cannabis use is linked to elevated psychosis risk, yet the neurobiological mechanisms that couple use to symptom expression remain unclear. Because glutamatergic dysregulation has been implicated in both cannabis effects and psychosis vulnerability, we examined whether brain glutamate relates to dimensional symptoms as a function of cannabis use across the psychosis spectrum....
PsyArXiv Preprints
June 25, 2026
Importance: Cannabis use (CU) in adolescence is linked to increased risk of developing psychotic-like experiences (PLEs) that can lead to lifelong impairment. A candidate mechanism may be disruptions in reward processing supported by dopamine but this association has not yet been tested in adolescents with CU and PLEs. The objective of the study was to assess the interrelation between CU, PLEs,...
Qualitative Sociology
June 23, 2026
Eduardo Durán
Abstract In this paper, I critically engage with Becker’s seminal work on marijuana consumption, challenging the notion of “becoming” a user as a straightforward process of taste acquisition. Drawing on the personal narratives of 38 current and former marijuana users, I show that “becoming” a marijuana user constitutes a dynamic state of tension rather than a linear trajectory with a terminal...
Journal of women's health (2002)
June 19, 2026
Michelle Nazareth, Victoria Paone, Mary Elizabeth Yaden et al.
Despite increasing interest in the medical use of substances such as cannabis and psychedelics, little is known about their use to manage premenstrual symptoms. This study assessed self-reported use of substances to manage premenstrual mood and physical symptoms, including among those with premenstrual dysphoric disorder (PMDD) and in perimenopause. Inclusion criteria were age 18 and older with...
Debates em Psiquiatria
June 9, 2026
L. Baldaçara, G. A. Rocha, Roberto Mendes Dos Santos et al.
Introduction: Cannabis use and the availability of high-potency cannabis-derived products and synthetic cannabinoids have increased worldwide, contributing to a growing burden of emergency presentations involving intoxication, agitation, psychosis, cardiovascular complications, and other acute toxic effects. Objective: This review aimed to update the clinical approach to emergencies related to...
Journal of Addiction Medicine
June 3, 2026
Ynhi T Thomas, Mubeen Iqbal, Chung J Mun et al.
Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical...
European Psychiatry
June 1, 2026
O. Rashid
Introduction In India’s context of an unregulated drug supply, psychosis is often attributed to cannabis based on patient history alone. However, the widespread contamination of substances with synthetic cannabinoids, opioids, and novel psychoactive substances (NPS) precipitates severe and atypical psychotic presentations that are frequently misdiagnosed as Cannabis-Induced Psychosis (CIP)....
Neuropharmacology
June 1, 2026
Evan C Smith, Christos Iliopoulos-Tsoutsouvas, Markos-Orestis Georgiadis et al.
Despite being the most prevalently abused illicit drug class, the neurochemical effects of cannabinoids (CBs) in key reward-related brain regions are not fully understood. Here, we used in vivo microdialysis combined with liquid chromatograph mass spectrometry to delineate how single, intraperitoneal injections of delta-9-tetrahydrocannabinol (Δ9-THC), and synthetic partial (AM11101) and full...
European Journal of Pharmacology
June 1, 2026
Gianluca Lavanco, Valentina Castelli, Cesare D'Amico et al.
Long-chain polyunsaturated fatty acids (LC-PUFAs) are crucial for brain development, with ω-3 species supporting neuronal membrane architecture, synaptogenesis and cognitive maturation, and ω-6 species linking lipid metabolism to neuronal signalling via the endocannabinoid system (ECS), the network of receptors, lipid mediators, and enzymatic pathways that orchestrate neurodevelopmental...